722 related articles for article (PubMed ID: 21782482)
1. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
2. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Urol Oncol; 2010; 28(3):285-9. PubMed ID: 18976938
[TBL] [Abstract][Full Text] [Related]
3. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
4. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Anticancer Res; 2009 Oct; 29(10):4201-4. PubMed ID: 19846973
[TBL] [Abstract][Full Text] [Related]
5. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
6. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
[TBL] [Abstract][Full Text] [Related]
7. Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer.
Lebret T; Becette V; Barbagelatta M; Hervé JM; Gaudez F; Barré P; Lugagne PM; Botto H
J Urol; 1998 Mar; 159(3):788-91. PubMed ID: 9474149
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
9. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
[TBL] [Abstract][Full Text] [Related]
10. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
13. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
[TBL] [Abstract][Full Text] [Related]
14. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
[TBL] [Abstract][Full Text] [Related]
15. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
16. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
17. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
Palou J; Algaba F; Vera I; Rodriguez O; Villavicencio H; Sanchez-Carbayo M
Eur Urol; 2009 Nov; 56(5):829-36. PubMed ID: 18926620
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer.
Cormio L; Sanguedolce F; Cormio A; Massenio P; Pedicillo MC; Cagiano S; Calò G; Pagliarulo V; Carrieri G; Bufo P
Oncotarget; 2017 Apr; 8(15):25433-25441. PubMed ID: 28445991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
